0001209191-23-038166.txt : 20230616 0001209191-23-038166.hdr.sgml : 20230616 20230616202704 ACCESSION NUMBER: 0001209191-23-038166 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230614 FILED AS OF DATE: 20230616 DATE AS OF CHANGE: 20230616 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: EHRLICH JASON CENTRAL INDEX KEY: 0001754049 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38682 FILM NUMBER: 231023021 MAIL ADDRESS: STREET 1: 1200 PAGE MILL ROAD CITY: PALO ALTO STATE: CA ZIP: 94304 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kodiak Sciences Inc. CENTRAL INDEX KEY: 0001468748 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270476525 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1200 PAGE MILL RD CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: 650-281-0850 MAIL ADDRESS: STREET 1: 1200 PAGE MILL RD CITY: PALO ALTO STATE: CA ZIP: 94304 FORMER COMPANY: FORMER CONFORMED NAME: Oligasis, LLC DATE OF NAME CHANGE: 20090721 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-14 0 0001468748 Kodiak Sciences Inc. KOD 0001754049 EHRLICH JASON 1200 PAGE MILL ROAD PALO ALTO CA 94304 0 1 0 0 See Remarks 1 Common Stock 2023-06-14 4 S 0 1132 9.42 D 58688 D Common Stock 2023-06-15 4 M 0 5494 A 64182 D Common Stock 2023-06-16 4 S 0 2258 9.23 D 61924 D Restricted Stock Units 2023-06-15 4 M 0 3619 0.00 D Common Stock 3619 3619 D Restricted Stock Units 2023-06-15 4 M 0 1875 0.00 D Common Stock 1875 3750 D The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units ("RSU") on June 11, 2023. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock. The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the RSUs on June 15, 2023. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). One-fourth (1/4th) of the RSUs vest on each of the first four anniversaries of June 15, 2020, subject to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date. One-fourth (1/4th) of the RSUs vest on each of the first four anniversaries of June 15, 2021, subject to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date. Chief Medical Officer and Chief Development Officer /s/ David Peinsipp, Attorney-in-Fact for Jason Ehrlich 2023-06-16